DCog Short for Neurotoxicity

This trial tests a new iPad app, DCog Short, to determine its effectiveness in assessing neurotoxicity (nerve damage) in individuals receiving CAR-T cell therapy, a cancer treatment. The goal is to quickly identify and treat patients experiencing nerve-related side effects. Participants will use the app daily during their hospital stay and continue through follow-up phone calls. Individuals who have undergone CAR-T cell therapy and have decent vision are encouraged to join. As an unphased trial, this study allows participants to contribute to innovative research that could enhance patient care.

The trial information does not specify whether you need to stop taking your current medications.

Research has shown that CAR T-cell therapy, which the DCog Short app assesses, can cause side effects. Studies have found that patients often experience neurotoxicity, affecting the brain and nervous system, with common symptoms like confusion and memory problems.

The DCog Short app is a tool for monitoring these side effects. No evidence suggests that using the app is unsafe, as it is not a drug or treatment but a means to track side effects.

Unlike traditional treatments for neurotoxicity, such as supportive care and corticosteroids, the DCog Short protocol is designed to proactively monitor and manage cognitive changes in patients undergoing CAR-T cell therapy. The unique approach involves frequent assessments during hospitalization and consistent follow-ups via phone, allowing for timely intervention. Researchers are excited about this trial because it aims to catch and address neurotoxic effects early, potentially improving patient outcomes and quality of life.

A previous study explored DCog Short as a tool to check for harmful effects on the nervous system in patients receiving CAR-T cell therapy. In the current trial, researchers designed it to detect changes in brain function by collecting self-reported data through an iPad app. Although direct proof of its effectiveness is not yet available, DCog Short aims to spot these harmful effects during treatment. This tool seeks to simplify patient monitoring and catch potential issues early. Initial findings suggest that technology like DCog Short could offer a promising and convenient way to track these changes.⁶⁷⁸⁹¹⁰